NEW YORK (GenomeWeb News) – Illumina said today that it has received premarket clearance from the US Food and Drug Administration for its MiSeqDx system, two cystic fibrosis assays, and a library prep kit that enables laboratories to develop their own diagnostic tests.

The designation marks the first time a next-generation sequencing system has received FDA premarket clearance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.